Nurix Therapeutics, Inc. — Form 10-Q Summary
Period clarification: The filing covers the quarter and six months ended May 31, 2023, not 2022 Q2 as stated in the request metadata. It was signed July 13, 2023.
Business context
Nurix is a clinical-stage biopharmaceutical company developing medicines that modulate cellular protein levels through its DELigase platform. Its wholly owned clinical programs include BTK degraders NX-2127 and NX-5948 and the CBL-B inhibitor NX-1607. The company also reports ten partnered discovery programs with Sanofi and Gilead. It has no approved products and has not generated product-sales revenue.
Financial results and position
| Metric | Three months ended May 31 | Six months ended May 31 |
|---|---|---|
| Total revenue | 2023: $30.7 million; 2022: $11.4 million | 2023: $43.4 million; 2022: $21.1 million |
| Net loss | 2023: $24.3 million; 2022: $45.4 million | 2023: $65.0 million; 2022: $87.9 million |
| Research and development expense | 2023: $45.8 million; 2022: $47.5 million | 2023: $91.6 million; 2022: $90.6 million |
| General and administrative expense | 2023: $11.7 million; 2022: $9.7 million | 2023: $21.5 million; 2022: $18.9 million |
| Net loss per share, basic and diluted | 2023: $0.45; 2022: $1.01 | 2023: $1.20; 2022: $1.96 |
Quarterly 2023 revenue included $20.0 million of license revenue from Gilead’s option exercise; the remaining $10.7 million was collaboration revenue. For the six-month period, collaboration revenue was $23.4 million. No product revenue was reported. The filing does not present a gross margin measure. Operating loss was $26.8 million for the quarter and $69.7 million for the six months.
At May 31, 2023, cash and cash equivalents were $59.0 million, current marketable securities $222.2 million and non-current marketable securities $27.5 million. Total assets were $350.6 million, total liabilities $90.7 million and stockholders’ equity $259.9 million. The company disclosed no financial debt; lease liabilities and other obligations are reported separately. Accumulated deficit was $466.3 million.
For the six months, operating cash use was $66.9 million, investing cash provided was $59.9 million, and financing cash provided was $1.5 million. Cash, cash equivalents and restricted cash decreased by $5.5 million to $59.9 million. Property and equipment purchases were $3.4 million. Operating lease commitments totaled approximately $43.5 million, including $7.7 million expected within twelve months.
Material changes versus prior comparable periods
- Revenue increased substantially, principally because of the one-time $20.0 million Gilead license payment. Excluding that license revenue, collaboration revenue was lower in Q2 2023 than Q2 2022, but higher for the six-month comparison.
- Net loss narrowed year over year in both the quarter and six-month period, while operating expenses were broadly similar. Higher interest and other income also contributed to the improvement.
- Six-month R&D expense increased slightly. Higher personnel, stock-based compensation, clinical and facility costs were partly offset by lower research, preclinical and contract manufacturing costs.
- Cash, cash equivalents and marketable securities totaled $308.6 million at May 31, 2023, down from $373.0 million at November 30, 2022.
Outlook, commentary and key risks
Management said available cash, cash equivalents and marketable securities should fund operations for at least twelve months after the financial statements’ issuance. It also stated that substantial additional funding will be needed to support the long-term plan and that existing resources will not fund the programs through commercialization. Management expects losses and expenses to continue, with R&D spending expected to rise as programs advance.
NX-2127, NX-5948 and NX-1607 were enrolling patients in Phase 1 trials. The company reported completing the safety run-in for DeTIL-0255 and deprioritizing its development; any trial expansion was to depend on whether NX-1607 might be included in future cohorts. Gilead exercised an option to license NX-0479, designated GS-6791, generating the $20.0 million payment; further milestone and royalty payments are contingent, not assured.
Key risks include early-stage clinical and scientific uncertainty, potential safety issues, patient enrollment and trial delays, reliance on third-party manufacturers and suppliers, collaboration-partner decisions, intellectual-property disputes, competition, and the need for additional capital. The filing identifies a third-party patent that may be alleged to cover targeted protein degraders including NX-2127 and NX-5948; Nurix says it believes it has defenses but cannot assure the outcome. Macro risks include inflation, higher interest rates, market volatility, banking-system instability and the war in Ukraine. The company reported no material legal proceedings and stated that disclosure controls were effective at May 31, 2023.
Important facts for investors to verify
- Confirm the reporting-period mismatch: the supplied metadata says 2022 Q2, while this filing reports the period ended May 31, 2023.
- Reconcile the filing’s liquidity figures: the balance sheet and notes show $281.2 million of cash, cash equivalents and current marketable securities, while MD&A cites $308.6 million including non-current marketable securities.
- Track cash burn against management’s stated minimum twelve-month runway and assess the timing and terms of any future financing.
- Assess clinical-trial progress, safety findings, enrollment and data quality for NX-2127, NX-5948 and NX-1607; early results may not predict later-stage outcomes.
- Review dilution exposure: 6,666,423 pre-funded warrants remained outstanding at May 31, 2023, and the filing reports 48,200,071 common shares outstanding as of June 30, 2023.
- Distinguish collaboration revenue and contingent milestone or royalty potential from recurring product revenue; no product sales have occurred.